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Abstract 
Germline mutations of BRCA1 predispose women to breast and ovarian cancers. Elucidating 
molecular mechanism of tissue- and gender-specific phenomena in BRCA1-related tumors is 
a key to our understanding of BRCA1 function in tumor suppression. This review summa-
rizes studies in recent years on the link between BRCA1 and estrogen/progesterone signal-
ing pathways, as well as discusses various models underscoring a triangle relationship among 
BRCA1, estrogen and genome instability.     
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Introduction 
Breast and ovarian cancer susceptibility gene 
BRCA1 was initially proposed by Mary-Claire King 
through linkage analysis in large cohorts of heredi-
tary breast cancer families [1] and was subsequently 
cloned in 1994 by Mark Skolnick and his col-
leagues[2]. Mutations in BRCA1 account for about 
half of the hereditary form of breast cancer and 
80-90% of hereditary breast-ovarian cancers [2, 3]. 
Genetic testing in existing clinical samples and newly 
registered breast cancer families quickly revealed 
several distinct features about BRCA1. First, BRCA1 
is clearly a tumor suppressor as loss of heterozygosity 
(LOH) in tumor samples from BRCA1-related 
breast/ovarian cancer invariably resulted in the loss 
of the wild type (WT) copy of BRCA1 and retention of 
the inherited mutant copy. Second, BRCA1 exerts its 
tumor suppression function in a gender- and tis-
sue-specific manner. Germline mutations of BRCA1 
predominantly lead to breast and/or ovarian cancer 
in women. Third, unlike mutations of the classic tu-
mor suppressor p53 that are associated with both he-
reditary and sporadic cancers, somatic mutations in 
the BRCA1 coding region are rarely associated with 
sporadic breast or ovarian cancer. 
A wealth of information from the research in the 
last two decades on the classical tumor suppressors 
such as p53 and Rb has facilitated mechanistic studies 
of BRCA1 in tumor suppression. Indeed, there is a 
striking functional similarity between BRCA1 and 
p53. A large body of evidence indicates that BRCA1 
plays a pivotal role in DNA damage response in-
cluding DNA repair and cell cycle checkpoint control 
[4-7]. Although the exact role of BRCA1 in DNA re-
pair remains to be elucidated, the overwhelming evi-
dence in the literature supports the notion that 
BRCA1 contributes to the maintenance of genome 
stability mainly through its function in DNA repair. 
The function of BRCA1 in DNA damage response 
provides a reasonable molecular explanation for its 
role as a tumor suppressor. Compromised functions 
of BRCA1 in DNA repair and cell cycle checkpoint 
likely contribute in a significant manner to cancer 
susceptibility. However, BRCA1 is ubiquitously ex-
pressed; and loss of BRCA1 function in maintenance 
of genetic stability, a cellular function that is funda-
mental and universally important to all cell types in 
both genders, cannot easily explain why it would in-
crease cancer risks in such a gender- and tis-
sue-specific manner. Furthermore, it is not clear why Int. J. Biol. Sci. 2009, 5 
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somatic mutations of BRCA1, which are expected to 
lead to genome instability, are rarely found in spo-
radic cancers [8]. 
The studies of BRCA1 functions in DNA repair 
and genome stability have dominated the BRCA1 
field since its discovery. In comparison, understand-
ing of the intriguing tissue- and gender-specificity 
associated with BRCA1 tumor suppression is a less 
traveled road. While the role of estrogen in sporadic 
breast cancer development has been widely studied, 
the potential interplay between BRCA1 and the hor-
mone synthesis and actions had been surprisingly 
under-appreciated and under-investigated in BRCA1 
field. Nevertheless, the striking restriction of 
BRCA1-related tumors to the major hor-
mone-responsive tissues begs the question as to 
whether the tumor suppressor function of BRCA1 is 
linked to the hormone homeostasis in the breast and 
ovaries. In addition, epidemiological studies have 
demonstrated that prophylactic oophorectomy in 
women who carry BRCA1 mutations prevents occur-
rence and reoccurrence of breast cancer by 75%[9, 10], 
further supporting the involvement of hormone fac-
tors in BRCA1-related tumor development. In this 
review, I will briefly summarize the published stud-
ies that attempted to address the BRCA1 function in 
hormone signaling and regulation. I will discuss the 
challenges in tackling tissue-specific tumor suppres-
sors and speculate on the underlying mechanisms for 
tissue-specific tumor suppression in general.   
BRCA1 in transcriptional regulation and tu-
mor suppression   
BRCA1 is a multi-functional protein. BRCA1 has 
been implicated in transcriptional regulation in addi-
tion to DNA repair and cell cycle checkpoint [11-13]. 
When fused to a heterologous DNA binding domain, 
the BRCA1 C-terminus confers transcriptional activ-
ity in reporter assays [14-16]. BRCA1 has also been 
shown to complex with RNA polymerase II 
holo-enzyme and a number of well-characterized 
transcription factors [13, 17]. When ectopically ex-
pressed, BRCA1 has been shown to regulate expres-
sion of multiple endogenous genes. In a cell-free sys-
tem, BRCA1 is capable of both stimulating and re-
pressing transcription in an in vitro transcription as-
say[18, 19]. Although the fact that BRCA1 is not a se-
quence-specific binding protein compounded the 
challenge of studying its function in transcription, 
circumstantial evidence supports that BRCA1 is in-
volved in transcriptional regulation. The critical 
question is: Is transcription function of BRCA1 re-
lated to its tumor-suppressor function, or is change in 
gene transcription just an innocent bystander in 
BRCA1-initiated tumor development?   
An inclusive view is that both DNA repair and 
transcriptional functions of BRCA1 contribute to its 
role in tumor suppression. Loss of BRCA1 function in 
DNA repair leads to genomic instability and, eventu-
ally, cancer. However, such effect alone would 
unlikely be tissue-specific. On the other hand, tran-
scriptional regulation by BRCA1 could be tissue- or 
cell type-specific, which could exacerbate the ge-
nomic instability in certain tissues and, therefore, in-
crease the penetrance of tumor development in these 
tissues. In other words, the combined loss of function 
in both DNA repair and transcription could lead to 
tissue-specific tumors. While deregulation of multiple 
BRCA1 target genes identified so far [20-25] could 
contribute to tumor development, I will focus on the 
published results that shed light on a link between 
BRCA1 and hormone-dependent transcription. 
BRCA1 and Estrogen Receptor   
The connection between BRCA1 and the hor-
mone signaling pathway was first brought to light by 
Eliot Rosen in 1999[26], whose group reported that 
ectopically expressed BRCA1 inhibits signaling by the 
ligand-activated estrogen receptor (ER-α) in an es-
trogen responsive reporter assay. Their follow-up 
studies demonstrated that BRCA1 also blocks the ex-
pression of two endogenous estrogen-responsive 
genes, pS2 and cathepsin D [27]. Furthermore, ge-
nome-wide microarray analyses revealed a large 
number of estrogen-responsive genes whose expres-
sion can be modulated by exogenous BRCA1[28]. The 
negative regulation of ER-α activity by BRCA1 results 
from either direct interaction between the BRCA1 
N-terminus (aa 67-100 and 101-133) and the 
ligand-binding domain/activation function-2 
(LBD/AF-2) region of ER-α, or BRCA1 
down-regulation of p300, a nuclear receptor cofactor 
[27, 29]. The initial observation is supported by find-
ings from other investigators as well [30]. It has been 
shown that BRCA1 also mediates the 
ligand-independent repression of ER-α [31]. 
The BRCA1 function in repression of ER-α tran-
scriptional activity provides a compelling explanation 
for the tissue- and gender-specific phenomenon in 
BRCA1-related tumors. A conundrum of this model 
is that BRCA1-derived breast cancer cells are ER-α 
negative. It has been suggested (model #1) that regu-
lation of ER-α function by BRCA1 exerts its 
anti-proliferation effect indirectly on potential ERα- 
tumor cells through paracrine pathways from 
neighboring ERα+ cells. Alternatively (model #2), the Int. J. Biol. Sci. 2009, 5 
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ERα- breast cancer cells may derive from ERα+ cells. 
In support of this notion, Chu-Xia Deng’s group re-
ported that mice carrying conditional Brca1 knockout 
in their mammary gland developed mammary gland 
tumors that were ERα+ at early stages, but 
became ERα- at later stages [32]. It is con-
ceivable that genomic instability of human 
breast cancer cells in earlier stages would 
eventually lead to estrogen-independent 
proliferation of the cancer cells. These ERα- 
cancer cells would ultimately comprise the 
entire tumor population, as they have a 
significant growth advantage over hor-
mone-dependent cells. Deng’s mouse 
model explains why ER-α could still play a 
role in ERα- breast cancer initiation and 
progression. It remains to be addressed 
why the tumor cells are almost exclusively ERα- cells 
and why very few ERα+ tumors derive from this 
pathway. This is in stark contrast to sporadic breast 
cancers, most of which are ERα+, where estrogen also 
plays a pivotal role. In fact, animal studies showed 
that activation of the estrogen signaling pathway col-
laborates with loss of Brca1 to promote both ERα- and 
ERα+ mammary tumor development [33], suggesting 
that ERα+ tumor cells would not be excluded by loss 
of mouse Brca1. The answer to the ERα- nature of 
BRCA1-related breast cancer may lie in another in-
terplay of BRCA1 and hormone action. It has been 
reported that ER-α activates BRCA1 expression 
[34-36](Fig.1). Therefore, in ERα+ cells, the elevated 
BRCA1 would provide additional protection in DNA 
damage response and genome stability maintenance. 
The benefits from ER-α associated genome stability 
cancels the slight risk from ER-α mediated prolifera-
tion. In contrast, ERα- cells have no added genome 
protection from ERα-mediated BRCA1 elevation. This 
model suggests that ERα- cells have the advantage in 
cancer initiation. The third model is that BRCA1 acti-
vates ER-α expression, proposed by Hosey et al. 
[37](Fig.1). As a result, loss of BRCA1 in precancerous 
cells would lead to genome instability as well as lack 
of ER-α expression. Combined with Deng’s model, 
Hosey’s result suggests a possibility that ERα- is a 
result of cancer progression, rather than the cause for 
initiation. Interestingly, Max Wicha’s group reported 
that BRCA1 is required for the differentiation of ERα- 
stem/progenitor cells to ERα+ luminal cells [38]. They 
hypothesize that BRCA1-mediated genome instability 
in mammary stem cells ultimately leads to breast 
cancer in women carrying germline mutations of 
BRCA1. In this context, absence of ERα could be a 
byproduct of cells lacking functional BRCA1 (consis-
tent with Hosey’s finding that BRCA1 is a positive 
regulator of ERα expression), but not a pre-requisite 
for tumor development.   
 
Fig.1 The interplay between ERα and BRCA1 pathways and 
its impact on cell proliferation (1) and genome stability 
maintenance (2). Solid arrows indicate a direct role while 
the dashed arrow indicates an indirect pathway (e.g. via a 
paracrine pathway etc.) 
 
The emerging picture shows that the crosstalk 
between BRCA1 and ER-α pathways exerts a com-
plicated network on cell proliferation and genome 
stability. Although the complete picture is lacking, it 
is likely that the combination of agonistic and an-
tagonistic actions of hormone somehow results in 
preferential development of breast cancer in ERα- 
cells. 
BRCA1 and Progesterone Receptor (PR), An-
drogen Receptor (AR) Pathways 
In addition to estrogen, the progester-
one-mediated signaling pathway also contributes to 
breast cancer development. The crosstalk between 
estrogen and progesterone pathways may have syn-
ergistic effect on breast cancer initiation and progres-
sion, as hormone replacement therapy (HRT) with 
combined estrogen and progesterone increased breast 
cancer risk in postmenopausal women [39-41]. Re-
search from both cell culture and animal models 
suggests that BRCA1 negatively modulates the pro-
gesterone receptor signaling pathway. Since proges-
terone receptors (PRA and PRB) are also target genes 
that are up-regulated by ER-α, one might predict that 
BRCA1 represses the PR pathway by inhibiting ER-α 
activity. This indirect mechanism might contribute to 
the inverse relationship between BRCA1 expression 
and PR activity in tissue culture and animal models. 
However, there is more to the story. Eliot Rosen’s Int. J. Biol. Sci. 2009, 5 
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group reported that BRCA1 directly interacts with 
PRA or PRB to repress their transcription activity on 
luciferase reporters as well as endogenous proges-
terone-responsive genes [42]. They show that absence 
of functional BRCA1 sensitizes progesterone signal-
ing in both T47D cells and mouse mammary gland, 
presumably due to removal of repression normally 
mediated by BRCA1. In an independent study, Eva 
Lee’s group demonstrated that BRCA1 
down-regulates PR protein level by affecting PR pro-
tein stability [43]. This is due to the presence of wild 
type BRCA1 that leads to polyubiquitination and 
degradation of PR. More importantly, treatment of 
Brca1/p53-deficient mice with progesterone antago-
nist mifepristone (RU 486) prevented mammary tu-
morigenesis, providing additional in vivo evidence of 
the involvement of the progesterone signaling path-
way in BRCA1-related mammary tumor develop-
ment. 
The epidemiological data regarding PR expres-
sion and BRCA1 status is limited and controversial at 
this point. One study reported that BRCA1 mutation 
carriers have reduced PR expression and, even strik-
ingly, lack of expression of the PRB isoform in pro-
phylactically removed normal breast tissue [44]. An-
other study reported that PR expression is increased 
in the benign epithelium of BRCA1-related breast 
cancers [45]. The discrepancy could be due to the in-
trinsic difference between normal tissue and benign 
cells surrounding the cancer cells. Alternatively, it 
could be due to the fact that each study used rela-
tively small sample numbers. 
The molecular mechanism of BRCA1 on PR 
activity shares some similarities to that of BRCA1 
on ER-α activity. This mechanism also shares the 
same conundrum that BRCA1-related cancers tend 
to be both ERα- and PR-negative. While the same 
argument that helped explain ERα action can be 
used to explain PR action, this is certainly a para-
dox remained to be experimentally explored in the 
future. 
Intriguingly, there has been one report that 
BRCA1 increases AR transcription activity, al-
though its significance to breast cancer develop-
ment remains to be elucidated [46].   
BRCA1 and Estrogen Biosynthesis   
Estrogen signaling plays a significant role in 
the development and progression of breast cancer. 
The research on estrogen receptors has provided tre-
mendous insight into our understanding of estrogen 
signaling and functions. Ablation of ER function by 
selective ER modulators such as tamoxifen has 
proven to be highly efficacious in breast cancer 
treatment. At the same time, the clinical importance 
of estrogen biosynthesis is underscored by the great 
success of aromatase inhibitors (AI) in breast cancer 
treatment. Aromatase, a key enzyme in estrogen bio-
synthesis, catalyzes the last and rate-limiting step in 
estrogen biosynthesis that converts androgen to es-
trogen [47] [48]. In recent years, aromatase inhibitors 
have demonstrated greater clinical efficacy in treating 
ERα+ postmenopausal breast cancer. Interestingly, 
several groups made unexpected connection between 
BRCA1 and aromatase. 
It has been well established that circulating es-
trogen level in pre-menopausal women is dictated by 
aromatase expressed in ovarian granulosa cells, 
whereas in many post-menopausal breast cancer and 
endometrial malignancy tissues, the aromatase pro-
duced in situ is significantly elevated [49, 50]. Expres-
sion of aromatase in multiple tissues is controlled by 
tissue-specific promoters and alternative splicing 
[51](Fig.2). Aromatase in ovarian granulosa cells is 
expressed mainly via the action of an ovary-specific 
promoter (PII). Intriguingly, the utilization of the 
aromatase promoter in many post-menopausal breast 
cancer and endometrial malignancy tissues is 
switched from the relatively weak adipose type pro-
moter (I.4) to the more potent ovarian type promoter 
(PII). Thus, the ovary-specific PII promoter of aroma-
tase is the primary determinant for both the circulat-
ing level of estrogen in pre-menopausal women and 
intratumoral aromatase expression in 
post-menopausal women. 
 
 
Fig.2 The genomic locations of several tissue-specific 
promoters of the aromatase gene (CYP 19) and tis-
sue-specific alternative splicing patterns of the aromatase 
transcripts. Int. J. Biol. Sci. 2009, 5 
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Ovarian expression of aromatase occurs in a cell 
type-specific and developmental stage-dependent 
manner. In response to the pituitary-released follicle 
stimulating hormone (FSH), aromatase expression is 
significantly increased in ovarian granulosa cells 
from follicles at the large antral/preovulatory (PO) 
stage [52]. FSH increases the intracellular cyclic AMP 
(cAMP) level, which ultimately activates the aroma-
tase PII promoter via the combined action of the 
CREB family of transcription factors and steroido-
genic factor 1 (SF-1).   
In situ hybridization of ovaries from adult mice 
has detected very low levels of Brca1 mRNA in ovar-
ian epithelial cells, the cell type from which 
BRCA1-associated ovarian cancer is thought to de-
rive[34, 53]. Instead, Brca1 expression is predomi-
nantly follicular, with the highest levels of Brca1 
mRNA in granulosa cells of developing follicles. In-
terestingly, ovarian expression of Brca1 was signifi-
cantly decreased at the large antral/preovulatory 
(PO) stage [54], a follicular stage where aromatase 
expression is significantly increased[55]. Therefore, 
there appears to be an inverse correlation between 
Brca1 and aromatase expression under this physio-
logical context, raising the possibility that there may 
be a causal relationship between these two events. 
These observations from mouse in situ hybridization 
raised an intriguing possibility of potential functional 
link between BRCA1 and aromatase expression in the 
same ovarian cell type.   
Based on the above-mentioned observation, we 
hypothesized that BRCA1 negatively regulates aro-
matase expression from ovary-specific promoter PII, 
and ovarian granulosa cells containing inherited mu-
tant BRCA1 would have elevated basal aromatase 
expression [56]. Using a human granulosa cell line 
that maintains physiological response to 
cAMP-mediated aromatase expression, we were able 
to recapitulate the inverse correlation between 
BRCA1 and aromatase expression level in a tissue 
culture model. When aromatase expression is in-
duced in response to cAMP activation, the BRCA1 
level is significantly reduced in granulosa cells cul-
tured  in vitro. Furthermore, knockdown of endoge-
nous BRCA1 by small interfering RNA (siRNA) leads 
to elevated aromatase basal expression. More impor-
tantly, the increased aromatase expression results 
from elevated ovary-specific promoter activity. Al-
though the molecular mechanism of BRCA1 regula-
tion of the aromatase promoter is not fully under-
stood, these data raised the possibility that BRCA1 
mutation carriers might have increased basal circu-
lating estrogen levels throughout their reproductive 
years, while their peak estrogen level during the 
menstrual cycle may not be affected, as there is no 
detectable BRCA1 expression (whether wild type or 
mutant) in granulosa cells at the preovulatory stage. 
It is this long-term elevated estrogen basal level that 
could potentially increase the breast cancer risk for 
women with germline mutations in BRCA1.   
The notion that BRCA1 down-regulates the 
aromatase expression in ovarian granulosa cells is 
consistent with the clinical observation that prophy-
lactic oophorectomy reduces the occurrence and 
re-occurrence of breast cancers in BRCA1 mutation 
carriers. However, the benefits of oophorectomy on 
breast cancer reduction could also be explained solely 
by deprivation of estrogen/progesterone on inhibit-
ing breast cancer cell proliferation, as in the case of 
sporadic breast cancer that does not involve BRCA1 
mutations. An independent study using conditional 
knockout mouse model provided strong in vivo evi-
dence for a cell non-autonomous function of BRCA1 
in ovarian granulosa cells in tumor suppression [57]. 
Using ovarian granulosa-specific Cre driven by the 
FSH receptor promoter, Dubeau’s group showed that 
female mice with BRCA1 knockout specifically in 
ovarian granulosa cells developed benign tumors on 
the uterine horn and the ovaries. Importantly, these 
tumors all had wild type BRCA1, suggesting that lack 
of BRCA1 in ovarian granulosa cells leads to tumori-
genesis in a paracrine manner. 
It appears that BRCA1 not only regulates aro-
matase expression in ovarian granulosa cells, it also 
modulates the ovary-specific aromatase promoter in 
adipose tissues, as shown in primary adipose fibro-
blasts derived from either breast or abdominal tissues 
[58, 59]. It is conceivable that mutant BRCA1 contrib-
utes to elevated circulating estrogen level as well as in 
situ estrogen expression in breast tissues.   
The notion that BRCA1 negatively regulates es-
trogen biosynthesis in non-epithelial cells also pro-
vides reasonable explanation for the gen-
der-specificity of BRCA1 cancer and the rare associa-
tion of somatic mutations of BRCA1 with sporadic 
breast cancer. If elevated estrogen production due to 
BRCA1 mutations in ovarian granulosa cells and 
adipose stromal cells constitutes a significant con-
tributing factor in BRCA1-associated tumor devel-
opment, male BRCA1 mutation carriers would obvi-
ously be exempt from such hormonal influence, de-
spite presumably the same degree of predisposition 
to genetic instability as their female counterparts due 
to the BRCA1 mutation status. Likewise, somatic 
BRCA1 mutations within sporadic breast tumor cells, 
albeit increasing genetic instability of the tumor cells, 
are unlikely to enhance aromatase expression in ova-
ries or adipose tissue. This could explain why somatic Int. J. Biol. Sci. 2009, 5 
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mutations of BRCA1 are rarely found in sporadic 
breast cancer. In contrast, women with germline mu-
tations of BRCA1 would have the elevated genetic 
instability in breast epithelial cells and increased es-
trogen production in non-epithelial cells from estro-
gen-producing tissues/organs, the combination of 
which could lead to tissue- and gender-specific can-
cer in BRCA1 mutation carriers.   
The linkage between BRCA1 and estrogen bio-
synthesis also provides another angle with which to 
address the conundrum that BRCA1-related tumors 
are generally ER-α negative. In addition to stimulat-
ing cell proliferation mediated by ER-α, it has been 
suggested that estrogen exerts a direct tumorigenic 
effect due to the fact that estrogen metabolic products 
could serve as carcinogens that induce free radi-
cal-mediated DNA damage and genetic instability 
[60]. In other words, estrogen has an ER-independent 
role in tumorigenesis. This could render 
ERα-negative cells more vulnerable as they do not 
have the benefit of elevated BRCA1 to protect ge-
nome stability as do ERα-positive cells.   
The Interplay of BRCA1 and Hormone Sig-
naling 
The emerging picture of BRCA1 in hormone 
signaling and action indicates that the pathway is not 
simple, linear, and unidirectional. As mentioned 
above, the estrogen/ER pathway induces BRCA1 ex-
pression. While BRCA1 represses ERα signaling and 
aromatase expression, it is also a positive regulator 
for ERα expression. The interplay between BRCA1 
and hormone pathways likely maintain the balance of 
two opposing effects: tumorigenic or tumor suppres-
sion. When BRCA1 is mutated, the balance is tilted 
towards tumorigenic, especially in ERα-negative 
cells, which lack the beneficial outcome from 
ERα-mediated BRCA1 expression and subsequent 
genome stability protection.   
The effect of hormone on BRCA1-related cancer 
development is certainly more complicated than we 
would like to believe. On one hand, oophorectomy 
significantly reduces the breast cancer risk in BRCA1 
mutation carriers, strongly suggesting that hormones 
play a pivotal role in BRCA1-related tumor develop-
ment, as in sporadic breast cancer. On the other hand, 
hormone (especially estrogen) levels seem to have the 
opposite effect on breast cancer occurrence in BRCA1 
mutation carriers and in sporadic breast cancers. For 
instance, early pregnancy is known to reduce breast 
cancer risk in the general population, while BRCA1 
mutation carriers are especially susceptible to breast 
cancer during pregnancy [61, 62]. This is consistent 
with the observation that increased exposure to es-
trogen has both beneficial and harmful effects on the 
breast in the general population depending on age. It 
has been proposed that elevated circulating estrogen 
levels play a duel role [63]. Estrogen increases breast 
cancer risk in postmenopausal women, because it 
stimulates the proliferation of precancerous cells that 
have accumulated genomic mutations in the breast 
tissues over years. In contrast, young women have 
not had the time to accumulate mutations in their 
cells and therefore, the protection from estro-
gen-induced BRCA1 expression and genome stability 
out-weighs the potential harm from estrogen-induced 
cell proliferation. In BRCA1 mutation carriers, how-
ever, the beneficial effect of estrogen is partially lost 
due to the presence of mutant BRCA1. As a result, 
elevated estrogen will only increase breast cancer 
risk, even in young women. Once again, this could be 
explained by tilting the balance of agonistic and an-
tagonistic estrogen effects. [63] 
 The multi-functional role of BRCA1 in hor-
mone expression and signaling has provided a start-
ing point to address the tissue- and gender-specificity 
in BRCA1 related cancer, but, at the same time, it 
raises more questions: Why do BRCA1-associated 
tumors develop in some estrogen-responsive tissues 
(breast and ovary), but not others (endometrium etc)? 
Why do only about 70% of the BRCA1 mutation car-
riers develop breast and/or ovarian cancer by age of 
70 years, while the rest (30%) are tumor free [3, 64, 
65]? Why is the penetrance of BRCA1 mutation in this 
generation much higher than that in the pre-war 
generation [66]? Clearly, other factors in addition to 
hormone pathways influence the tumor development 
in BRCA1 mutation carriers. These factors may in-
clude tissue microenvironment, other varia-
tions/modifiers such as the genetic makeup and 
life-style/environment impact on the individual.   
It is intrinsically more challenging to study tu-
mor development in an endocrine/paracrine system, 
as compared to studying DNA repair function, which 
can be conducted in cells taken out of the context of 
organs/tissues. Tissue-culture-based mechanistic 
studies of BRCA1 function in breast tumor cells have 
provided tremendous insight into BRCA1 functions 
in the maintenance of genomic stability and modula-
tion of ER activity. The intriguing link between 
BRCA1 and estrogen synthesis in non-epithelial cells 
highlights importance of understanding the tissue- 
and gender-specific tumor suppressor function of 
BRCA1 in a physiologically relevant context. Hope-
fully, with infusion of fresh ideas from in-
ter-disciplinary fields and innovative research ap-Int. J. Biol. Sci. 2009, 5 
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proaches, more light will be shed on this clinically 
important and intellectually interesting question.   
An Added Note 
Tissue-specific tumor suppressors are not lim-
ited to BRCA1. Other tumor suppressors, such as 
BRCA2, RB and APC, also display certain degree of 
tissue specificity or preference in tumor spectrum 
when LOH occurs. For example, LOH of APC leads 
to familial adenomatous polyposis coli, RB leads to 
retinoblastoma [67], while loss of these tumor sup-
pressors in somatic cells lead to broader tumor spec-
tra. In these cases, the difference in familial and spo-
radic tumor spectra may well be attributed to their 
transcription impact in vivo. i.e., loss of genome sta-
bility would lead to tumor occurrence in multiple 
tissues, as in the case of sporadic tumors resulting 
from somatic mutations of these genes. However, in 
germline mutation carriers, every cell carries the mu-
tation and its impact on transcription varies tissue to 
tissues and cell type to cell type. This could render 
certain tissues more susceptible to tumor develop-
ment. The transcription regulation could take place in 
situ (cell-specific gene expression in the same cells 
from which cancer derives) or in different cells (affect 
cancer cells via endocrine or paracrine pathways). 
One would predict that, in both cases, it would lead 
to tumor in preferred tissues, and in the second case, 
predominantly to familial cancer. In other words, the 
same concept of dual functions in both epithelial and 
non-epithelial cells could be potentially applied to the 
understanding of the tissue specificity or preference 
of tumors that arise from the loss of other tumor sup-
pressors such as APC and Rb.   
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